ITGAX promotes cell proliferation, migration, and invasion ability both in vitro and in vivo by activating the epithelial-mesenchymal transition pathway, characterized by the downregulation of epithelial markers like E-cadherin and upregulation of mesenchymal markers such as N-cadherin and vimentin, facilitates tumor progression and metastasis. The gene discussed is CDH2; the disease is neoplasm.